TY - JOUR
T1 - Study of tamoxifen in metastatic renal cell carcinoma and the influence of certain prognostic factors
T2 - A Southwest Oncology Group study
AU - Al-Sarraf, M.
AU - Eyre, H.
AU - Bonnet, J.
AU - Saiki, J.
AU - Gagliano, R.
AU - Pugh, R.
AU - Lehane, D.
AU - Dixon, D.
AU - Bottomley, R.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 1981
Y1 - 1981
N2 - A prospective study of tamoxifen therapy in doses of 10 mg twice daily was carried out in 79 patients with advanced renal cell cancer. The objective response rate (complete response plus partial response) was 6.3% (five of 79 patients), while 34.1% (27 of 79 patients) had stable disease. Survival of this group of patients (complete response plus partial response plus stable disease) was significantly longer than that of patients with progressive disease (P < 0.04). Also, among patients with a good performance status at the beginning of the study, survival was longer than among those with a poor performance status (P < 0.001). No statistical significance was found in the survival of these patients according to sex (P = 0.55) or whether or not they had received previous systemic therapy (P = 0.97). Toxicity was low and acceptable. We concluded that stratification according to performance status may be used in future randomized systemic therapy protocols for patients with metastatic renal cell cancer. Also, in spite of the low response rate to hormonal therapy including tamoxifen, the use of these agents with combination chemotherapy may enhance the overall response rate without increasing side effects.
AB - A prospective study of tamoxifen therapy in doses of 10 mg twice daily was carried out in 79 patients with advanced renal cell cancer. The objective response rate (complete response plus partial response) was 6.3% (five of 79 patients), while 34.1% (27 of 79 patients) had stable disease. Survival of this group of patients (complete response plus partial response plus stable disease) was significantly longer than that of patients with progressive disease (P < 0.04). Also, among patients with a good performance status at the beginning of the study, survival was longer than among those with a poor performance status (P < 0.001). No statistical significance was found in the survival of these patients according to sex (P = 0.55) or whether or not they had received previous systemic therapy (P = 0.97). Toxicity was low and acceptable. We concluded that stratification according to performance status may be used in future randomized systemic therapy protocols for patients with metastatic renal cell cancer. Also, in spite of the low response rate to hormonal therapy including tamoxifen, the use of these agents with combination chemotherapy may enhance the overall response rate without increasing side effects.
UR - http://www.scopus.com/inward/record.url?scp=0019495360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019495360&partnerID=8YFLogxK
M3 - Article
C2 - 7237466
AN - SCOPUS:0019495360
SN - 0361-5960
VL - 65
SP - 447
EP - 451
JO - Cancer Treatment Reports
JF - Cancer Treatment Reports
IS - 5-6
ER -